Document is current
Any future updates will be listed below
-
Authors
Sebastin, Monisha
Odgis, Jacqueline A.
Suckiel, Sabrina A.
Bonini, Katherine E.
Di Biase, Miranda
Brown, Kaitlyn
Marathe, Priya
Kelly, Nicole R.
Ramos, Michelle A.
Rodriguez, Jessica E.
Aguiñiga, Karla López
Lopez, Jessenia
Maria, Estefany
Rodriguez, Michelle A.
Yelton, Nicole M.
Cunningham-Rundles, Charlotte
Gallagher, Katie
McDonald, Thomas V.
McGoldrick, Patricia E.
Robinson, Mimsie
Rubinstein, Arye
Shulman, Lisa H.
Wolf, Steven M.
Yozawitz, Elissa
Zinberg, Randi E.
Abul-Husn, Noura S.
Bauman, Laurie J.
Diaz, George A.
Ferket, Bart S.
Greally, John M.
Jobanputra, Vaidehi
Gelb, Bruce D.
Horowitz, Carol R.
Kenny, Eimear E.
Wasserstein, Melissa P. http://orcid.org/0000-0003-2031-7817
-
Funding
Funding for this research was provided by:
National Human Genome Research Institute (1U01HG009610-01)
- License Information
-
More Information
Article History
Received: 18 October 2021
Accepted: 2 February 2023
First Online: 22 March 2023
Declarations
:
: This study protocol has been approved by the Institutional Review Boards of Icahn School of Medicine at Mount Sinai and Albert Einstein College of Medicine. Digitally signed, informed consent to participate will be obtained from all participants.
: A model consent form will be made available upon request.
: EEK has received speaker honorariums from Regeneron and Illumina. NSAH was previously employed by Regeneron Pharmaceuticals, has received a speaker honorarium from Genentech, and is a scientific advisory board member for Allelica. AB has received consulting fees from the American Board of Family Medicine outside the submitted work. JCB has received an honorarium from LivaNova. AR has received funding by TAKEDA for two clinical trials: HYQVIA in Pediatric CVID Patients (2018–2021) and SCIG Treatment for Chronic Inflammatory Demyelinating Polyneuropathy. RZ has received consulting fees from Sema4 outside the submitted work. All other authors declare they have no competing interests.
